Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283153 | 0.87 | MGLL (0.39) | ALDH1A1SMN1; SMN2LMNAMGLLGAA | |
| SCHEMBL23673709 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL11124856 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL11121877 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL7793042 | 0.79 | GRIN1 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL7035041 | 0.79 | GRIN1 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL908580 | 0.79 | GRIN1 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL28326008 | 0.79 | GRIN1 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL5959164 | 0.79 | GRIN1 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL23089775 | 0.77 | MEN1 (0.35) | ALDH1A1LMNAMGLLGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050220983-A1 | Method of processing a stack of coatings and apparatus for processing a stack of coatings | 3D SYSTEMS, INC. | 2005-10-06 | — | — | US | claimed |
| US-20050173045-A1 | Method of registering and bonding coatings to form a part, apparatus for manufacturing a part | 3D SYSTEMS, INC. | 2005-08-11 | — | — | US | claimed |
| EP-1507645-A1 | A METHOD OF REGISTERING AND BONDING COATINGS TO FORM A PART, APPARATUS FOR MANUFACTURING A PART | Hayes, Jonathan (GB) | 2005-02-23 | — | — | EP | claimed |
| EP-1506082-A1 | A METHOD OF PROCESSING A STACK OF COATINGS AND APPARATUS FOR PROCESSING A STACK OF COATINGS | Hayes, Jonathan (GB) | 2005-02-16 | — | — | EP | claimed |
| WO-2003095183-A1 | A METHOD OF REGISTERING AND BONDING COATINGS TO FORM A PART, APPARATUS FOR MANUFACTURING A PART | HAYES JONATHAN (GB) | 2003-11-20 | — | — | WO | claimed |
| WO-2003095182-A1 | A METHOD OF PROCESSING A STACK OF COATINGS AND APPARATUS FOR PROCESSING A STACK OF COATINGS | HAYES JONATHAN (GB) | 2003-11-20 | — | — | WO | claimed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-8008342-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2011-08-30 | — | — | US | disclosed |
| US-20110207730-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2011-08-25 | — | — | US | disclosed |
| US-7875611-B2 | (+)-trans-[2-(4-morpholinyl)-1-[2-(2-naphthoxy)ethoxy)]; (1R,2R)/(1S,2S)-2-[1,4-dioxa-7-azaspiro[4.4]non-7-yl]-1-(1-naphthenethoxy)cyclohexanecyclohexane; treatment of arrhythmia and the production of analgesia and local anesthesia | CARDIOME PHARMA CORP. (CA) | 2011-01-25 | — | — | US | disclosed |
| WO-2003095182-A1 | A METHOD OF PROCESSING A STACK OF COATINGS AND APPARATUS FOR PROCESSING A STACK OF COATINGS | HAYES JONATHAN (GB) | 2003-11-20 | — | — | WO | disclosed |
| EP-0720605-B1 | AMINOCYCLOHEXYLESTERS AND USES THEREOF | UNIV BRITISH COLUMBIA (CA) | 2001-12-19 | — | — | EP | disclosed |
| EP-1087934-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | Nortran Pharmaceuticals Inc. (CA) | 2001-04-04 | — | — | EP | disclosed |
| US-6174879-B1 | BLOCKING SODIUM AND POTASSIUM ION CHANNELS IN VIVO AND IN VITRO; ANTIARRHYTHMIA AGENTS | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-01-16 | — | — | US | disclosed |
| WO-1999050225-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | NORTRAN PHARMACEUTICALS INC. (CA) | 1999-10-07 | — | — | WO | disclosed |
| EP-0720605-A1 | AMINOCYCLOHEXYLESTERS AND USES THEREOF | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008544-A1 | AMINOCYCLOHEXYLESTERS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | ALDH1A1 1319/4885SMN1; SMN2 2646/4885LMNA 2669/4885 |
| US-20110207730-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | ALDH1A1 1319/4885SMN1; SMN2 2646/4885LMNA 2669/4885 |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | ALDH1A1 4238/4885SMN1; SMN2 2670/4885LMNA 2720/4885 |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | ALDH1A1 1319/4885SMN1; SMN2 2646/4885LMNA 2669/4885 |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | ALDH1A1 1319/4885SMN1; SMN2 2646/4885LMNA 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.